Kashif Rashid - Nevro Corp Executive
| NVRO Stock | USD 4.55 0.03 0.66% |
Executive
Mr. Kashif Rashid has served as our General Counsel, Corporationrationrate Secretary and Chief Compliance Officer since December 2017. From March 2017 to December 2017, Mr. Rashid served as Vice President, Legal at Atara Biotherapeutics, Inc., a biotechnology company focused on Tcell immunotherapy. From June 2008 to February 2017, Mr. Rashid served first as Associate General Counsel and later as Deputy General Counsel at St. Jude Medical, Inc., a medical device company. From September 1998 to June 2008, Mr. Rashid served in roles of increasing responsibility at General Electric Company Healthcare business, Loews Corporation and Kaye Scholer, LLP, a global law firm since 2020.
| Age | 50 |
| Tenure | 4 years |
| Address | 1800 Bridge Parkway, Redwood City, CA, United States, 94065 |
| Phone | 650 251 0005 |
| Web | https://nevro.com |
Latest Insider Transactions
Rashid received a B.S. in Business Administration from the George Washington University and a J.D. from Georgetown University Law Center.Kashif Rashid Latest Insider Activity
Tracking and analyzing the buying and selling activities of Kashif Rashid against Nevro Corp stock is an integral part of due diligence when investing in Nevro Corp. Kashif Rashid insider activity provides valuable insight into whether Nevro Corp is net buyers or sellers over its current business cycle. Note, Nevro Corp insiders must abide by specific rules, including filing SEC forms every time they buy or sell Nevro Corp'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Kashif Rashid over a month ago Disposition of 479 shares by Kashif Rashid of Nevro Corp at 4.97 subject to Rule 16b-3 | ||
Kashif Rashid over two months ago Disposition of 1759 shares by Kashif Rashid of Nevro Corp at 5.18 subject to Rule 16b-3 | ||
Kashif Rashid over three months ago Disposition of 479 shares by Kashif Rashid of Nevro Corp at 8.38 subject to Rule 16b-3 | ||
Kashif Rashid over six months ago Disposition of 817 shares by Kashif Rashid of Nevro Corp at 9.52 subject to Rule 16b-3 |
Nevro Corp Management Efficiency
The company has return on total asset (ROA) of (0.0902) % which means that it has lost $0.0902 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.2478) %, meaning that it created substantial loss on money invested by shareholders. Nevro Corp's management efficiency ratios could be used to measure how well Nevro Corp manages its routine affairs as well as how well it operates its assets and liabilities. As of the 26th of November 2024, Return On Tangible Assets is likely to drop to -0.17. In addition to that, Return On Capital Employed is likely to drop to -0.19. At this time, Nevro Corp's Non Current Assets Total are very stable compared to the past year. As of the 26th of November 2024, Intangible Assets is likely to grow to about 33 M, while Total Assets are likely to drop about 461.8 M.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Julie Andrews | Orthofix Medical | 53 | |
| Robert JD | Paragon 28 | 57 | |
| Mehul Joshi | Pulmonx Corp | 63 | |
| Kimberly Lockwood | CONMED | N/A | |
| Brent Lalomia | CONMED | 49 | |
| John Shumaker | Paragon 28 | N/A | |
| David JD | Pulmonx Corp | 63 | |
| Ahmet Tezel | LivaNova PLC | N/A | |
| Kelley Nicholas | Neuropace | N/A | |
| Steve Kachelmeyer | Iradimed Co | N/A | |
| Chris Williamson | Iradimed Co | N/A | |
| Oliver Moravcevic | Rxsight | N/A | |
| Dylan John | Neuropace | N/A | |
| Leah Akin | Neuropace | N/A | |
| Chris Calcaterra | Glaukos Corp | 64 | |
| Christopher Lewis | Glaukos Corp | N/A | |
| Joel Batts | Orthopediatrics Corp | N/A | |
| John Harris | Integer Holdings Corp | 64 | |
| Matthew Jarboe | Paragon 28 | 41 | |
| Mark Karshner | Orthopediatrics Corp | N/A | |
| Sarah Huber | Pulmonx Corp | N/A | |
Management Performance
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0902 |
Nevro Corp Leadership Team
Elected by the shareholders, the Nevro Corp's board of directors comprises two types of representatives: Nevro Corp inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Nevro. The board's role is to monitor Nevro Corp's management team and ensure that shareholders' interests are well served. Nevro Corp's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Nevro Corp's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Julie Dewey, Vice President - Investor Relations and Corporate Communications | ||
| Elizabeth Weatherman, Independent Director | ||
| Brad Vale, Independent Director | ||
| Donald Middlebrook, Vice President - Clinical, Regulatory and Quality | ||
| Christopher Christoforou, Vice President - Research and Development | ||
| Kevin OBoyle, Independent Director | ||
| Meredith Vornholt, Vice Marketing | ||
| Kashif JD, Senior Officer | ||
| Peter Socarras, General VP | ||
| Shawn McCormick, Independent Director | ||
| David Caraway, Chief Medical Officer | ||
| Christofer Christoforou, Senior Operations | ||
| DKeith Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Patrick Schmitz, Vice President - Operations | ||
| Richard Carter, Chief Officer | ||
| Sridhar Kosaraju, Director | ||
| Frank Fischer, Independent Director | ||
| Michael DeMane, Lead Independent Director | ||
| Kevin Thornal, CEO President | ||
| Roderick MacLeod, Chief Financial Officer | ||
| Greg Siller, Senior Officer | ||
| Shana MBA, Senior Officer | ||
| Michael Carter, Vice President - Global Sales | ||
| D Grossman, Chairman of the Board, President, Chief Executive Officer | ||
| Susan Siegel, Independent Director | ||
| Karen Prange, Independent Director | ||
| Angeline McCabe, Vice Communications | ||
| Kashif Rashid, Chief Compliance Officer, General Counsel, Corporate Secretary | ||
| Geeta Kaveti, VP Officer | ||
| Niamh Pellegrini, Chief Commercial Officer | ||
| Lori Ciano, Chief Human Resource Officer | ||
| David MD, Senior Officer | ||
| Jon Shear, Senior Development |
Nevro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Nevro Corp a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.25 | ||||
| Return On Asset | -0.0902 | ||||
| Profit Margin | (0.17) % | ||||
| Operating Margin | (0.16) % | ||||
| Current Valuation | 138.92 M | ||||
| Shares Outstanding | 37.47 M | ||||
| Shares Owned By Insiders | 3.71 % | ||||
| Shares Owned By Institutions | 98.09 % | ||||
| Number Of Shares Shorted | 3.14 M | ||||
| Price To Earning | (63.38) X |
Pair Trading with Nevro Corp
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Nevro Corp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Nevro Corp will appreciate offsetting losses from the drop in the long position's value.Moving against Nevro Stock
| 0.52 | DOCS | Doximity | PairCorr |
| 0.5 | VMD | Viemed Healthcare | PairCorr |
| 0.45 | FOXO | FOXO Technologies | PairCorr |
| 0.32 | ITGR | Integer Holdings Corp | PairCorr |
The ability to find closely correlated positions to Nevro Corp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Nevro Corp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Nevro Corp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Nevro Corp to buy it.
The correlation of Nevro Corp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Nevro Corp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Nevro Corp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Nevro Corp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Nevro Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area. To learn how to invest in Nevro Stock, please use our How to Invest in Nevro Corp guide.You can also try the Latest Portfolios module to quick portfolio dashboard that showcases your latest portfolios.
Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Nevro Corp. If investors know Nevro will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Nevro Corp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.87) | Revenue Per Share 11.404 | Quarterly Revenue Growth (0.07) | Return On Assets (0.09) | Return On Equity (0.25) |
The market value of Nevro Corp is measured differently than its book value, which is the value of Nevro that is recorded on the company's balance sheet. Investors also form their own opinion of Nevro Corp's value that differs from its market value or its book value, called intrinsic value, which is Nevro Corp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Nevro Corp's market value can be influenced by many factors that don't directly affect Nevro Corp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Nevro Corp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Nevro Corp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Nevro Corp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.